Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Nanchang Hongyi Pharmaceutical Co., Ltd., established on 2002-11-26, Business scope includes raw materials(levamlodipine besylate,Diisopropylamine dichloroacetate,tiotropium bromide),Granules(AWire,BWire),Pills,dry suspension,inhalation preparation(Powder spray),tablet(Contains traditional Chinese medicine pretreatment and extraction)production,Sales;Self-operated or agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)**

Nanchang Hongyi Technology Co., Ltd., established on 1998-01-04, Business scope includes pharmaceutical,Health products,Technology development in food chemical industry,technology transfer,technical consulting,Technical Services(The operating permit) **

Provincial Health Services Authority (PHSA) is a publicly funded health service provider in the province of British Columbia. Other health authorities in the province have a regional jurisdiction. PHSA is unique in Canada as the only health authority having a province-wide mandate for specialized health services. Services are provided either directly through PHSA agencies or through funding or collaboration with regional health authorities.

At Kura Oncology, They are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how they treat cancer. They now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. They are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Their development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.

Signal Pharmaceuticals is a biopharmaceutical company that was founded by David Anderson (Senior VP & Head of Research), Alan Lewis (CEO), Mark Carmen, and Jackie Johnson and is based in California. It was acquired by Celgene in 2009

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

CSPC Yuanda (Dalian) Pharmaceutical Co., Ltd. engages in the production and sale of pharmaceutical products. The company was founded on November 25, 1998 and is headquartered in Dalian, China.

The Japanese Cancer Research Foundation supports the establishment of a cancer institute and its affiliated hospital. It has been leading the research and treatment of cancer thru activities integrating basic and clinical research. It shows their accomplishments in cancer research and treatment over a long history. It is one of the the world-s institutes in bioscience. They are making accomplishments in the treatment of cancer its related diseases with efficient medical staff and leading-edge medical equipment.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with Ewing's sarcoma.

NanoValent Pharmaceuticals develops novel therapeutic options with enhanced target and delivery characteristics. Their technology will significantly enhance therapeutics. It possesses an experienced core management team with a proven track record of success, supported by a strong clinical and operational capability.

Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.